-
Kphb Branch+91 9111674111
-
Tarnaka Branch
+91 9100001201
- Book Appointment
+91 9111674111
+91 9100001201
General Medicine
BA.3.2, sometimes called the “Cicada” variant, is a SARS-CoV-2 lineage that WHO continues to list as a Variant Under Monitoring. This guide separates established surveillance information from early laboratory findings and explains symptoms, testing, treatment, prevention and when to seek medical care.
BA.3.2 is a SARS-CoV-2 lineage under WHO monitoring. WHO lists it as a Variant Under Monitoring (VUM). Its genetic changes are being tracked, but current WHO surveillance does not establish that BA.3.2 causes more severe disease than other circulating variants. Symptoms overlap with other COVID-19 infections, so symptoms alone cannot identify BA.3.2.
Evidence period: The WHO surveillance summary cited here covers 30 August–27 September 2026. It does not provide live Hyderabad case numbers. Variant prevalence and risk assessments can change.
BA.3.2 is a SARS-CoV-2 lineage. “Cicada” is a nickname used in public discussion; BA.3.2 is the formal lineage designation. WHO designated BA.3.2 as a Variant Under Monitoring on December 5, 2025, and lists its earliest documented sample as November 22, 2024.
Not on the evidence currently summarized by WHO. A Variant Under Monitoring designation means a lineage is being tracked because of characteristics that merit surveillance; it does not itself mean the virus causes more severe disease. WHO’s dashboard summary for 30 August–27 September 2026 reported no additional public-health risk from BA.3.2 relative to other circulating variants. This is a dated assessment, not a guarantee about future behaviour or an individual patient’s illness.
There is no symptom pattern that reliably distinguishes BA.3.2 from other SARS-CoV-2 infections. Possible symptoms include:
| Feature | COVID-19 | Flu | Common cold |
|---|---|---|---|
| Fever | Possible | Common | Less common |
| Cough | Common | Common | Common |
| Sore throat | Possible | Possible | Common |
| Runny/stuffy nose | Possible | Possible | Common |
| Body aches | Possible | Often prominent | Usually milder |
| Loss of taste/smell | Possible | Less typical | Less typical |
Symptoms overlap substantially, so testing may be appropriate when the result could affect treatment or precautions.
BA.3.2 has numerous genetic changes, including changes in the spike protein that are relevant to immune-recognition research. Laboratory studies can help researchers understand antibody neutralization, but laboratory immune-escape findings are not the same as proof that vaccines no longer protect people from severe disease.
Vaccine protection varies with the vaccine formulation, time since vaccination, previous infection and individual risk factors. Vaccination remains an important tool for reducing the risk of severe COVID-19. Follow current vaccination recommendations for your age and risk group rather than changing vaccination decisions because of social-media claims about BA.3.2.
If you are at higher risk and develop COVID-19 symptoms, early medical advice can be important because some antiviral treatments have a limited treatment window.
A negative rapid antigen test early in illness does not always exclude COVID-19. Follow the test instructions and clinical advice about repeat testing or a laboratory test. Seek help for concerning symptoms even without a positive result.
Routine antigen or laboratory molecular tests can identify SARS-CoV-2 infection. Most routine patient tests do not identify the exact variant. Variant identification generally requires genomic sequencing or specialized surveillance testing.
There is no separate “Cicada variant” medicine. Treatment is based on illness severity and individual risk:
Fever, cough, sore throat and fatigue in Hyderabad can have many causes, including COVID-19, influenza and other respiratory infections. General Medicine can provide an initial assessment and determine whether testing, treatment or specialist care is appropriate. My Health Hospitals has General Medicine consultations at Kukatpally and Tarnaka; confirm current doctor availability and timings before visiting.
MBBS, MD – General Medicine | General Physician & Diabetologist
General Medicine physician at My Health Hospitals, Kukatpally, Hyderabad.
The Cicada COVID variant is the nickname used for SARS-CoV-2 lineage BA.3.2. WHO lists BA.3.2 as a Variant Under Monitoring.
BA.3.2 was designated by WHO as a Variant Under Monitoring in December 2025 and continues to be tracked in 2026.
Cicada is a nickname used in public discussion. The formal lineage name is BA.3.2.
Symptoms can include fever, sore throat, cough, runny or blocked nose, fatigue, headache and body aches. Some people may have gastrointestinal symptoms or breathing difficulty.
Current WHO surveillance information does not establish that BA.3.2 causes more severe disease than other circulating variants.
A claim that BA.3.2 is universally more transmissible should not be made without current comparative surveillance evidence.
Most routine COVID-19 tests identify SARS-CoV-2 infection rather than a specific lineage. Variant identification generally requires genomic sequencing or specialized surveillance testing.
Vaccine protection varies by formulation, time since vaccination and individual factors. Vaccination remains an important tool for reducing severe COVID-19 risk.
Post-COVID conditions can occur after SARS-CoV-2 infection, but available information does not support attributing a specific long-COVID risk to BA.3.2 without stronger evidence.
Risk is generally higher in older adults and people with certain chronic conditions or weakened immune systems.
Consider COVID-19 testing when appropriate, reduce close contact while unwell, rest and hydrate, and contact a clinician early if you are at higher risk.
Seek urgent care for severe breathing difficulty, persistent chest pain or pressure, new confusion, inability to stay awake, blue or grey discoloration, severe dehydration or rapidly worsening illness.
Many mild COVID-19 infections can be managed with supportive care at home, but treatment depends on symptoms and risk factors.
Antibiotics do not treat SARS-CoV-2. They are used when a clinician identifies a bacterial infection or another appropriate indication.
Diabetes can be associated with a higher risk of complications from COVID-19. People with diabetes should follow individualized medical advice.
Variant circulation changes over time and should be assessed using the latest Indian and WHO genomic surveillance data.
For non-emergency symptoms, General Medicine can provide an initial clinical assessment. My Health Hospitals has General Medicine consultations at Kukatpally and Tarnaka.
Yes. SARS-CoV-2 surveillance is continuously updated, and WHO can change variant classifications and risk assessments as new evidence becomes available.
If symptoms persist or worsen, or you are at higher risk of severe COVID-19, seek individualized medical advice.
My Health Hospitals – General Medicine: +91 9111674111
Find Our Kukatpally and Tarnaka Branches
H.No 15-24-212, MIG-212, Rd Number 1, K P H B Phase 1, Kukatpally, Hyderabad, Telangana 500072
H.No:-12-5-30, WhiteHouse, Moula Ali Rd, South Lalaguda, Tarnaka, Secunderabad, Telangana 500017